United States First Circuit

ResetAA Font size: Print

Amphastar Pharms., Inc. v. Momenta Pharms., Inc., 16-2113

In a dispute among competitors in the United States market for generic enoxaparin, an anticoagulant, alleging antitrust violations of the Sherman Act 15 U.S.C. sections 1 and 2 by defendants, predicated upon the defendants' alleged misrepresentations to the United States Pharmacopeial Convention (USP), a private standard-setting organization (SSO) charged with ensuring the quality of drugs, the district court's dismissal of the complaint under the so-called Noerr-Pennington doctrine, which immunizes good-faith petitioning of government entities from antitrust liability, where the district court erroneously applied Noerr-Pennington.

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2017/03/06




  • United States First Circuit


FindLaw Career Center

      Post a Job  |  View More Jobs

    View More